The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialA. Huijbers, Wilma E. Mesker, Susan Dutton et al.|Annals of Oncology|2012Cited by 348
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M.S. Bartlett, Christopher Poole, Alison F. Munro et al.|The Lancet Oncology|2010Cited by 127